NuChem Sciences
NuChem Sciences is a contract research organization based in Montréal that specializes in drug discovery services for the pharmaceutical and biotechnology sectors. It serves a diverse clientele that includes biotech companies, pharmaceutical firms, and academic research laboratories across North America. The organization offers a wide array of services in medicinal chemistry and drug discovery biology, encompassing fragment screening, structure-activity relationship design, and computational drug design. By providing relevant data and expertise, NuChem Sciences aims to support its clients in advancing their projects efficiently in various therapeutic areas such as inflammation, diabetes, cancer, obesity, infectious diseases, and pain management.
Top Regions
Top Stages
2 past transactions
IniXium
Acquisition in 2022
IniXium, founded in 2014, is a contract research organization that offers structural biology expertise to the biotech and pharmaceutical sectors. The company specializes in producing and biophysically characterizing recombinant proteins, performing protein crystallography, fragment screening, and developing biologics and biosimilars. By employing X‑ray crystallography as its core technology, IniXium supplies critical data that accelerates early‑phase drug discovery projects.
OmegaChem
Acquisition in 2021
OmegaChem is a contract research organization focused on drug discovery and fine chemical manufacturing for the pharmaceutical industry. The company specializes in custom synthesis and process chemistry, providing research and development contracts that assess biological activities. OmegaChem aims to enhance customer outcomes by increasing yields, minimizing processing steps, and allowing for modifications in the quantities and types of reagents used. This approach helps reduce manufacturing costs and improve the scalability and safety of synthetic processes for various molecules.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.